CL2009001044A1 - Compuestos cristalinos derivados de heterociclos puenteados por un alqueno; utiles en el tratamiento de enfermedades metabolicas, enfermedades circulatorias, enfermedades del snc, entre otras enfermedades. - Google Patents

Compuestos cristalinos derivados de heterociclos puenteados por un alqueno; utiles en el tratamiento de enfermedades metabolicas, enfermedades circulatorias, enfermedades del snc, entre otras enfermedades.

Info

Publication number
CL2009001044A1
CL2009001044A1 CL2009001044A CL2009001044A CL2009001044A1 CL 2009001044 A1 CL2009001044 A1 CL 2009001044A1 CL 2009001044 A CL2009001044 A CL 2009001044A CL 2009001044 A CL2009001044 A CL 2009001044A CL 2009001044 A1 CL2009001044 A1 CL 2009001044A1
Authority
CL
Chile
Prior art keywords
diseases
heterocycles
bridged
alkene
useful
Prior art date
Application number
CL2009001044A
Other languages
English (en)
Inventor
Kuroita Takanobu
Sakamoto Hiroki
Igawa Hideyuki
Sasaki Ninoru
Asano Kouhei
Maekawa Tsuyoshi
Fuji Koji
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2009001044A1 publication Critical patent/CL2009001044A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos cristalinos derivados de heterociclos puenteados por un alqueno; útiles en el tratamiento de enfermedades metabólicas, enfermedades circulatorias, enfermedades del SNC, entre otras enfermedades.
CL2009001044A 2008-05-02 2009-04-30 Compuestos cristalinos derivados de heterociclos puenteados por un alqueno; utiles en el tratamiento de enfermedades metabolicas, enfermedades circulatorias, enfermedades del snc, entre otras enfermedades. CL2009001044A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/114,048 US7803940B2 (en) 2006-11-24 2008-05-02 Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases

Publications (1)

Publication Number Publication Date
CL2009001044A1 true CL2009001044A1 (es) 2010-08-27

Family

ID=40935778

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001044A CL2009001044A1 (es) 2008-05-02 2009-04-30 Compuestos cristalinos derivados de heterociclos puenteados por un alqueno; utiles en el tratamiento de enfermedades metabolicas, enfermedades circulatorias, enfermedades del snc, entre otras enfermedades.

Country Status (7)

Country Link
US (3) US7803940B2 (es)
AR (1) AR071531A1 (es)
CL (1) CL2009001044A1 (es)
PE (1) PE20091881A1 (es)
TW (1) TW201004944A (es)
UY (1) UY31803A (es)
WO (1) WO2009133970A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200970510A1 (ru) * 2006-11-24 2009-12-30 Такеда Фармасьютикал Компани Лимитед Гетеромоноциклическое соединение и его применение
KR101107162B1 (ko) * 2009-12-02 2012-01-25 삼성모바일디스플레이주식회사 유기 발광 표시 장치
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
US9499461B2 (en) 2010-08-27 2016-11-22 Neonc Technologies, Inc. Pharmaceutical compositions comprising POH derivatives
ES3056006T3 (en) 2010-12-17 2026-02-17 Univ Southern California Methods and devices for using isoperillyl alcohol
WO2012107814A1 (en) * 2011-02-08 2012-08-16 Jubilant Life Sciences Limited An improved process for the preparation of azilsartan medoxomil
GB2497806A (en) * 2011-12-21 2013-06-26 Ono Pharmaceutical Co Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
JP6454348B2 (ja) 2013-12-19 2019-01-16 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 窒素複素環誘導体およびその医薬品への応用
SI3125894T1 (sl) 2014-04-01 2020-12-31 Merck Sharp & Dohme Corp. Predzdravila inhibitorjev reverzne transkriptaze HIV
WO2016093285A1 (ja) 2014-12-10 2016-06-16 小野薬品工業株式会社 ジヒドロインドリジノン誘導体
WO2016130800A2 (en) 2015-02-12 2016-08-18 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
CN110831593A (zh) * 2017-06-14 2020-02-21 特维娜有限公司 用于调节s1p1活性的化合物及其使用方法
WO2019055832A1 (en) * 2017-09-15 2019-03-21 The Regents Of The University Of California COMPOSITIONS AND METHODS FOR INHIBITING N-SMASE2
JP2021512165A (ja) 2018-01-29 2021-05-13 コグノス・セラピューティクス・インコーポレイテッド ボルテゾミブの腫瘍内送達
KR102131022B1 (ko) * 2018-07-12 2020-07-07 보령제약 주식회사 피리미디논 유도체 화합물 및 이의 용도
MX2022005766A (es) 2019-11-19 2022-08-08 Trevena Inc Compuestos y métodos para la preparación de compuestos moduladores de esfingosina 1-fosfato tipo 1 (s1p1).

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411980A (en) 1989-07-28 1995-05-02 Merck & Co., Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
ATE113281T1 (de) 1989-08-02 1994-11-15 Takeda Chemical Industries Ltd Pyrazol-derivate, verfahren zu deren herstellung und anwendung.
DE69129998T2 (de) 1990-02-15 1998-12-24 Takeda Chemical Industries, Ltd., Osaka Pyrimidindionderivate, deren Herstellung und Verwendung
CA2037630C (en) 1990-03-07 2001-07-03 Akira Morimoto Nitrogen-containing heterocylic compounds, their production and use
US5166206A (en) 1990-03-30 1992-11-24 Merck & Co., Inc. Substituted pyrimidines, pyrimidinones and pyridopyrimidines
AT395853B (de) 1991-01-31 1993-03-25 Chem Pharm Forsch Gmbh Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
US5472967A (en) 1991-02-20 1995-12-05 Synthelabo 4-pyrimidinone derivatives their preparation and their application in therapy
US5164403A (en) 1991-04-05 1992-11-17 G. D. Searle & Co. N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
IT1250749B (it) 1991-08-02 1995-04-21 Luso Farmaco Inst Composti eterociclici ad attivita' a ii antagonista
DE69333489T2 (de) 1992-09-14 2005-04-14 Takeda Chemical Industries, Ltd. Heterocyclische Verbindungen und ihre Verwendung als Angiotensin II Antagonisten
CA2143193A1 (en) 1992-10-13 1994-04-28 David B. Reitz N-arylheteroarylalkyl 1-phenyl-imidazol-2-one compounds for treatment of circulatory disorders
EP0603712B1 (en) 1992-12-22 2001-08-16 Takeda Chemical Industries, Ltd. Heterocyclic compounds having angiotensin II antagonistic activity and use thereof
DE69425250D1 (de) 1993-03-24 2000-08-17 Searle & Co 1-phenyl-imidazol-2-on bipehenylmethyl verbindungen zur behandlung von kreislaufstörungen
WO1995016677A1 (en) 1993-12-16 1995-06-22 Nkk Corporation Novel pyrimidine derivative and medicinal composition
FR2716883B1 (fr) 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
US20010020100A1 (en) 1994-06-14 2001-09-06 G.D. Searle & Co. N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders
DE4431218A1 (de) 1994-09-02 1996-03-07 Bayer Ag Substituierte Pyrimidin(thi)one
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
GB0506147D0 (en) 2005-03-24 2005-05-04 Merck Sharp & Dohme Therapeutic agents
DE102005030522A1 (de) 2005-06-30 2007-01-04 Bayer Healthcare Ag Salz des Embusartans
EA200970510A1 (ru) 2006-11-24 2009-12-30 Такеда Фармасьютикал Компани Лимитед Гетеромоноциклическое соединение и его применение

Also Published As

Publication number Publication date
WO2009133970A1 (en) 2009-11-05
US20090176812A1 (en) 2009-07-09
US20110112120A9 (en) 2011-05-12
US20100113780A1 (en) 2010-05-06
US7998968B2 (en) 2011-08-16
US7803940B2 (en) 2010-09-28
TW201004944A (en) 2010-02-01
US20100105709A1 (en) 2010-04-29
UY31803A (es) 2009-12-14
AR071531A1 (es) 2010-06-23
PE20091881A1 (es) 2009-12-24

Similar Documents

Publication Publication Date Title
CO6592104A2 (es) Compuesto heterociclico
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
EA201071032A1 (ru) Гетероциклическое соединение
MX2011010449A (es) Derivados de oxadiazol.
EA201171367A1 (ru) Винилиндазолильные соединения
UY34261A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-alcoxi-2-ciclil-etil}-1h-[1,2,4]triazol sustituidos
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
UY34593A (es) Miméticos sintéticos de apelina para el tratamiento de falla cardiaca
UY34765A (es) Compuestos novedosos.
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
CR20110357A (es) Polimorfos de (s)-3-amino-metil-7-(3-hidroxi-propoxi)-3h- benzo-(c) (1,2)-oxaborol-1-ol
ECSP077360A (es) Compuestos sulfonamida
CR20110432A (es) Pirimidinas fusionadas
CO6321273A2 (es) N-fenil -y - lactamas subtituidas las cuales son agonistas ep2 para ser usados como agentes terapeuticos para el tratamiento de glaucoma, sindrome del intestino irritable y calvicie
UY32125A (es) Compuestos novedosos como ligandos de receptores de canabinoides
CO6382123A2 (es) Antagonistas de la via hedgehog de ftalazina disustituida
PH12015502665A1 (en) Improvements in or relating to organic compounds
AR112787A2 (es) Compuestos 1,5-difenil-penta-1,4-dien-3-ona
UY34629A (es) Inhibidores de pirazolopirimidinilo de enzima activadora de ubicuitina
TN2011000355A1 (en) Novel microbiocides
AR093527A1 (es) 6-((S)-1-1-[5-(2-HIDROXI-ETOXI)-PIRIDIN-2-IL]1H-PIRAZOL-3-IL-ETIL)-3H-1,3-BENZOTIAZOL-2-ONA COMO UN ANTAGONISTA DEL RECEPTOR AMPA DEPENDIENTE DE TARP-g 8
PH12014501534A1 (en) Inhibitors of iap
GB201114389D0 (en) Novel compounds
UY34072A (es) Derivados sustituidos de indol